“…49,51,[54][55][56] However, most studies find no difference between PBSC and BM grafts for HLA-identical siblings or matched unrelated donor in relation to aGVHD or cGVHD incidence, 48,52,53 non-relapse mortality, 50,51 disease-free survival 50,51,[54][55][56] and OS. 48,[50][51][52][53] This study has some limitations: (i) small number of patients, (ii) small number of DCs circulating in PB, which may influence accuracy for DC measurements 57 and (iii) heterogeneity with regard to the underlying disease and the stem cell source. Accuracy may be improved by choosing markers with a better signal-to-noise ratio, for example, CD303 instead of CD123.…”